Summary:
To evaluate the safety and effectiveness of AZD6793 for adults with moderate to very severe chronic obstructive pulmonary disease COPD.
Qualified Participants Must:
• Be Age ≥ 40 years
•
Be Diagnosed with moderate to very severe COPD ≥ 12 months
•
Have had at least 1 COPD exacerbations in past 12 months
•
Stable triple or dual inhaled COPD therapy ≥ 3 months